Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:ENTX NASDAQ:IOBT OTCMKTS:SPHRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$1.89-3.1%$1.83$1.33▼$3.58$91.86M0.7463,875 shs53,762 shsENTXEntera Bio$1.78-2.7%$2.01$1.41▼$2.79$83.18M1.4667,499 shs130,051 shsIOBTIO Biotech$1.45+1.4%$1.28$0.66▼$1.73$94.21M0.36284,299 shs149,348 shsSPHRYStarpharma$0.64+8.9%$0.58$0.47▼$0.80$26.73M0.76142 shs500 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene-3.08%+2.16%-5.03%+35.00%-32.98%ENTXEntera Bio-2.73%-4.30%-14.01%+7.85%+0.56%IOBTIO Biotech+1.40%+5.07%-9.38%+65.15%+22.88%SPHRYStarpharma0.00%+8.88%+25.22%+8.32%+6.52%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADAGAdagene1.9985 of 5 stars3.33.00.00.01.81.70.0ENTXEntera Bio2.0339 of 5 stars3.55.00.00.00.00.80.0IOBTIO Biotech2.6406 of 5 stars3.73.00.00.00.62.50.6SPHRYStarpharmaN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 2.50Moderate Buy$8.00323.28% UpsideENTXEntera Bio 3.00Buy$10.00461.80% UpsideIOBTIO Biotech 3.33Buy$9.33543.68% UpsideSPHRYStarpharma 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SPHRY, IOBT, ADAG, and ENTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/14/2025IOBTIO BiotechHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$100K890.38N/AN/A$1.14 per share1.66ENTXEntera Bio$180K449.45N/AN/A$0.23 per share7.74IOBTIO BiotechN/AN/AN/AN/A$0.71 per shareN/ASPHRYStarpharma$6.40M4.18N/AN/A$0.45 per share1.42Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$33.42MN/A0.00N/AN/AN/AN/AN/A7/23/2025 (Estimated)ENTXEntera Bio-$9.54M-$0.26N/AN/AN/A-4,525.11%-95.10%-82.77%8/8/2025 (Estimated)IOBTIO Biotech-$95.49M-$1.49N/AN/AN/AN/A-162.55%-125.08%8/12/2025 (Estimated)SPHRYStarpharma-$5.36MN/A0.00∞N/AN/AN/AN/A8/20/2025 (Estimated)Latest SPHRY, IOBT, ADAG, and ENTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025ENTXEntera Bio-$0.07-$0.06+$0.01-$0.06N/A$0.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/AENTXEntera BioN/AN/AN/AN/AN/AIOBTIO BiotechN/AN/AN/AN/AN/ASPHRYStarpharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.012.302.30ENTXEntera BioN/A13.0713.07IOBTIO BiotechN/A2.322.32SPHRYStarpharmaN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%ENTXEntera Bio14.11%IOBTIO Biotech54.76%SPHRYStarpharmaN/AInsider OwnershipCompanyInsider OwnershipADAGAdagene21.20%ENTXEntera Bio10.38%IOBTIO Biotech2.30%SPHRYStarpharmaN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.11 million37.12 millionNot OptionableENTXEntera Bio2045.45 million40.73 millionOptionableIOBTIO Biotech3065.88 million64.37 millionNot OptionableSPHRYStarpharma4541.82 millionN/ANot OptionableSPHRY, IOBT, ADAG, and ENTX HeadlinesRecent News About These CompaniesSPHRY Starpharma Holdings LimitedJune 19, 2025 | seekingalpha.comChange in Substantial Holder’s Voting Power at Starpharma HoldingsJune 3, 2025 | tipranks.comPleasing Signs As A Number Of Insiders Buy Starpharma Holdings StockMay 5, 2025 | uk.finance.yahoo.comStarpharma Advances Strategic Initiatives and Expands Market PresenceApril 29, 2025 | tipranks.comIs Starpharma Holdings (ASX:SPL) In A Good Position To Deliver On Growth Plans?March 25, 2025 | finance.yahoo.comRobmar Investments Acquires Substantial Stake in Starpharma HoldingsMarch 17, 2025 | tipranks.comStarpharma Highlights DEP® Dendrimer Platform at PepTalk ConferenceJanuary 15, 2025 | tipranks.comAstodrimer by Starpharma for Coronavirus Disease 2019 (COVID-19): Likelihood of ApprovalDecember 30, 2024 | pharmaceutical-technology.comPStarpharma CEO Receives Major Performance Rights IssuanceDecember 12, 2024 | markets.businessinsider.comStarpharma Issues Unquoted Securities to Boost Employee IncentivesDecember 12, 2024 | markets.businessinsider.comStarpharma Holdings Reports Successful AGM ResultsNovember 29, 2024 | tipranks.comStarpharma Holdings Schedules Reconvened AGM for Key VoteNovember 26, 2024 | tipranks.comStarpharma AGM Results Highlight Voting ChallengesNovember 26, 2024 | tipranks.comStarpharma Holdings Highlights Strategic Advances in 2024November 25, 2024 | tipranks.comStarpharma Highlights Dendrimer Technology at Healthcare ConferenceNovember 18, 2024 | markets.businessinsider.comStarpharma Showcases Dendrimer Innovations at Microcap ConferenceOctober 29, 2024 | markets.businessinsider.comMedicxi, Starpharma create Petalion with $25M roundApril 9, 2024 | bioworld.comBMedicxi and Starpharma to develop dendrimer-based cancer treatmentsApril 8, 2024 | pharmaceutical-technology.comPStarpharma Holdings Ltd. ADRMarch 14, 2024 | wsj.comNews - StarpharmaFebruary 20, 2024 | thepharmaletter.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPHRY, IOBT, ADAG, and ENTX Company DescriptionsAdagene NASDAQ:ADAG$1.89 -0.06 (-3.08%) As of 07/8/2025 03:59 PM EasternAdagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Entera Bio NASDAQ:ENTX$1.78 -0.05 (-2.73%) Closing price 07/8/2025 03:44 PM EasternExtended Trading$1.87 +0.09 (+5.06%) As of 07/8/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.IO Biotech NASDAQ:IOBT$1.45 +0.02 (+1.40%) As of 07/8/2025 04:00 PM EasternIO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.Starpharma OTCMKTS:SPHRY$0.64 +0.05 (+8.88%) As of 07/3/2025Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom. It is also involved in the development of DEP cabazitaxel that is in Phase 2 clinical trial for the treatment of prostate and other cancers, DEP docetaxel that is in Phase 2 clinical trials for the treatment of colorectal and other cancers, DEP irinotecan that is in Phase 2 clinical trials f for the treatment of pancreatic and other cancers; and EP gemcitabine, DEP HER-2 ADC, and DEP HER-2 radiotherapy completed preclinical trials for the treatment of solid cancers. In addition, the company's DEP radiotheranostics development pipeline includes DEP HER2-zirconium, a HER2-targeted radio diagnostic for HER2-positive cancers, such as breast and gastric cancer; and HER2-targeted DEP SN38 ADC, a targeted ADC therapeutic for the treatment of human ovarian cancer. Starpharma Holdings Limited was incorporated in 1997 and is headquartered in Abbotsford, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
